IP Library Granted Patent US 10,596,176
Granted Patent B2
US 10,596,176 · App. 15/232,788 · Granted Mar 24, 2020

Methods to treat visual impairment

Inventors: Mark Firman Bear (Boston, MA); Kevin R. Duffy (Bible Hill, CA); Donald E. Mitchell (Halifax, CA); Ming-Fai Fong (Cambridge, MA); Arnold Heynen (Providence, RI); Jeffrey P. Gavornik (Cambridge, MA)
Assignee: Massachusetts Institute of Technology
A61K31/529A61K9/0048A61K31/137A61K31/167A61K31/216A61K31/245A61K31/381A61K31/4168A61K31/4174A61K31/445A61K31/4409A61K31/46A61K31/47A61K38/4893A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,596,176
App. No.
15/232,788
Granted
Mar 24, 2020
Kind
B2
Abstract

Amblyopia is a prevalent form of visual impairment that generally arises during infancy and early childhood when inputs to the visual cortex form the two eyes are poorly balanced. Disclosed herein are methods involving retinal inactivation of at least one retina to treat visual impairment in the form of amblyopia or other conditions.

Claims (16)

1. A method of treating amblyopia in a subject, the method comprising performing retinal inactivation in both retinas of the subject, wherein the retinal inactivation is performed by administering an anesthetic.

2. The method of claim 1 , wherein the anesthetic is a sodium channel blocker.

3. The method of claim 2 , wherein the sodium channel blocker is extracellular.

4. The method of claim 2 , wherein the sodium channel blocker is intracellular.

5. The method of claim 1 , further comprising administering an agent that enhances the effectiveness or duration of effect of an inactivator.

6. The method of claim 5 , wherein the agent that enhances the effectiveness or duration of effect of an inactivator is epinephrine clonidine or dexmedetomide.

7. The method of claim 1 , wherein the inactivator is administered by an intravitreal injection, a retrobulbar block, a sub-Tenon block, a peribulbar block, topically to the front of an eye or using an implanted device.

8. The method of claim 7 , wherein the inactivator is administered by an intravitreal injection.

9. The method of claim 1 , wherein the retinal inactivation persists for a period of time between 2 hours and 14 days.

10. The method of claim 9 , wherein the retinal inactivation persists for 6-72 hours.

11. The method of claim 1 , further comprising repeating performing retinal inactivation.

12. The method of claim 11 , wherein the performing retinal inactivation is repeated 1-7 times.

13. The method of claim 12 , wherein the performing retinal inactivation is repeated 1-4 times.

14. The method of claim 13 , wherein the performing retinal inactivation is repeated once.

15. The method of claim 11 , wherein the performing retinal inactivation is repeated 1-60 days after the previous retinal inactivation.

16. The method of claim 1 , further comprising performing or directing a surgical procedure or administering or directing the administration of a non-surgical treatment.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2020
From: BEAR, MARK FIRMAN; DUFFY, KEVIN R.; MITCHELL, DONALD E.; FONG, MING-FAI; HEYNEN, ARNOLD; GAVORNIK, JEFFREY P.; HOWARD HUGHES MEDICAL INSTITUTE
To: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
Reel/Frame 052005/0806 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2020
From: BEAR, MARK F.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 052005/0850 →
CONFIRMATORY LICENSE Recorded Nov 7, 2016
From: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 040570/0004 →
Continuity (2)
Provisional Application 62202908 · Aug 9, 2015
Related Publication 20170065598A1 · Mar 9, 2017